Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short
Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells and deliver targeted radiation.
Search results for "ADC"
Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal
Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes therapies—through the planned...
From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’
The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological...
MSD Bets $510M on High-Quality Data to Fuel Post-Keytruda AI Drug Discovery
MSD, which has long dominated the global cancer market with its blockbuster immuno-oncology therapy Keytruda, is...
Huwons Lab SC Formulation Change Platform, Will It Succeed in the Market?
Huwons Global's subsidiary Huwons Lab is challenging the formulation change platform business that converts intravenous...
Datroway Approved: New Targeted Therapy Offers Hope for Metastatic Breast Cancer
A new therapeutic horizon has arrived for patients battling metastatic breast cancer that has progressed despite...
K-Bio Targets Global Expansion: HK inno.N and HLB Seek FDA Approval
South Korean pharmaceutical and biotech companies are aggressively pursuing product approvals and clinical trials with...
LigaChemBio Receives Milestone from Czech Sotio Biotech
LigaChem Biosciences announced on the 9th that it will receive milestone payments based on successful product...
Dr. Han Jin-hwan, Formerly of Merck (MSD), Appointed Head of New Drug Research Institute at Ligand Pharmaceuticals
Ligand Pharmaceuticals announced on the 5th that it has recruited Dr. Han Jin-hwan, formerly of Merck, as the head of...